Authors
Andrea Álvarez-Vázquez, María Martínez-Fernández, Enrique Jiménez-Madrona, Josephine Volovetz, Susana Fraile-Martín, Sakura E Chan, Raúl González-Sánchez, Kristen E Kay, Sabrina Z Wang, Samuel A Sprowls, Daniel J Silver, Juyeun Lee, Justin D Lathia, Arantxa Tabernero
Published in
Cancer letters. Pages 218960. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
Glioblastoma (GBM) remains an incurable disease with an extremely poor prognosis. Tumor resection represents a first-line treatment when possible, but most patients suffer tumor recurrence, the primary cause of mortality. One of the functions of connexin43 (Cx43), a gap junction-forming subunit that also has a role in channel-independent signaling, is the inhibition of Src, an oncoprotein involved in tumor progression and recurrence. We previously developed a Cx43 mimetic peptide TAT-Cx43266-283 that recapitulates the inhibition of Src and exerts antitumor effects in patient-derived and mouse in vitro and in vivo models, and here we aimed to explore its effect in GBM recurrence. Analysis of clinical datasets shows a marked increase of Src activity after the standard of care treatments, suggesting that targeting Src activity could prevent GBM recurrence. Importantly, we found that the combination of tumor resection and TAT-Cx43266-283 extended survival in two syngeneic, immunocompetent GBM resection models, which recapitulated key complementary histological features of GBM. TAT-Cx43266-283 in combination with tumor resection increased tumor cell apoptosis and decreased important hallmarks of GBM recurrence by targeting the specific dominant features in each model, such as aberrant vascularization or tumor infiltration. These effects occurred alongside the recruitment of tumor-associated macrophages and microglia (TAMs) to tumor border and their shift towards an antitumor phenotype. Our findings suggest the possible involvement of the immune system in the antitumor effects of TAT-Cx43266-283 and reveal the efficacy and safety of the intracavitary application of TAT-Cx43266-283 after tumor resection, supporting its potential in a clinical setting.
PMID:
43014537
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0